Results of a Genome-Wide Linkage Analysis in Prostate Cancer Families Ascertained Through the ACTANE Consortium

Prostate

Volumn 57, Issue 4, 2003, Pages 270-279

  Eeles, Rosalinda ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ACTANE; Genome search; Linkage; Prostate cancer

Indexed keywords

ARTICLE; CANCER FAMILY; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CELL HETEROGENEITY; CHROMOSOME 18; CHROMOSOME 2; CLINICAL TRIAL; GENE LOCUS; GENETIC LINKAGE; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN GENOME; LINKAGE ANALYSIS; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

EID: 0344081176     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10301     Document Type: Article

References (49)

1. Verkasalo PK, Kaprio J, Koskenvuo M, Pukkala E. Genetic predisposition, environment and cancer incidence: A nationwide twin study in Finland, 1976-1995. Int J Cancer 1999;83:743-749.
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 2000;343:78-85.
3. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. A systematic population based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994;86:1600-1608.
4. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367-3371.
5. Grönberg H, Damber L, Damber J-E, Iselius L. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance. Am J Epidemiol 1997;146:552-557.
6. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998;62:1425-1438.
7. Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, Labrie F. The impact of family history on early detection of prostate cancer. Nature Med 1995;1:99-101.
8. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE. Evidence of an X-linked or recessive component to prostate cancer risk. Nature Med 1995;1:827-829.
9. Cui J, Staples MP, Hopper JL, English DR, McCredie MRE, Giles GG. Segregation analysis of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 2001;68: 1207-1218.
10. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-1374.
11. Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, Oesterling JE, Sandler HM, Lange K. Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study. J Natl Cancer Inst 1997;89:955-959.
12. Hsieh C-L, Oakley-Girvan I, Gallagher RP, Wu AH, Kolonel LN, Teh C-Z, Halpern J, West DW, Paffenberger RS Jr., Whittemore AS. Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study. J Natl Cancer Inst 1997;89:1893.
13. Neuhausen SL, Farnham JM, Kort E, Tavtigian S-V, Skolnick MH, Cannon-Albright LA. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet 1999;8:2437-2442.
14. Berry R, Schaid DJ, Smith JR, French AJ, Schroeder JJ, McDonnell SK, Peterson BJ, Wang ZY, Carpten JD, Roberts G, Tester DJ, Blute ML, Trent JM, Thibodeau SN. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000;66:539-546.
15. Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 2001;68:1197-1206.
16. Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley KE, Henning L, Ewing C, Bujnovszky P, Bleeker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet 2001; 108:335-345.
17. McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL, Hood L, Ostrander EA. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer susceptibility gene at 1q24-25. Am J Hum Genet 1997;61:347-353.
18. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Ellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cohen D, Cussenot O. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998;62:1416-1424.
19. Eeles RA, Simard J, Teare D, Edwards S, Durocher F, Badzioch M, Hamoudi R, Gill S, Biggs P, Dearnaley D, Ardern-Jones A, Dowe A, Shearer R, Ford D, Amos C, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Narod S, Easton D, Foulkes W. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet 1998; 62:653-658.
20. Bergthorsson JT, Johannesdottir G, Arason A, Benediktsdottir KR, Agnarsson BA, Bailey-Wilson JE, Gillanders E, Smith J, Trent J, Barkardottir RB. Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer. Hum Genet 2000;107: 372-375.
21. Goode EL, Stanford JL, Chakrabarti L, Gibbs M, Kolb S, McIndoe RA, Buckley VA, Schuster EF, Neal CL, Miller EL, Brandzel S, Hood L, Ostrander EA, Jarvik GP. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol 2000; 18:51-75.
22. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, Gillanders E, Sankila R, Pukkala E, Carpten J, Stephan D, Tammela T, Brownstein M, Bailey-Wilson J, Trent J, Kallioniemi OP. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: Frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000;6:4810-4815.
23. Xu J, the International Consortium for Prostate Cancer Genetics. Combined analysis of hereditary prostate cancer linkage to 1q24-25: Results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 2000;66:945-957.
24. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Grönberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-184.
25. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70:1299-1304.
26. Chen H, Griffin AR, Wu YQ, Tomsho LP, Zuhlke KA, Lange EM, Gruber SB, Cooney KA. RNASEL mutations in hereditary prostate cancer. J Med Genet 2003;40:e21.
27. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-180.
28. Meitz JC, Edwards SM, Easton DF, Murkin A, Ardern-Jones A, Jackson RA, Williams S, Dearnaley DP, Stratton MR, Houlston RS, Eeles RA, The Cancer Research UK/BPG UK Familial Prostate Cancer Study Collaborators. HPC2/ELAC2 polymorphisms and prostate cancer risk: Analysis by age of onset of disease. Br J Cancer 2002;87:905-908.
29. Camp NJ, Tavtigian SV. Associations of ELAC2 variants and prostate cancer. Am J Hum Genet 2002;71:1475-1478.
30. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J, Grönberg H, Emanuelsson M, Damber J-E, Bergh A, Jonsson B-A, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998;20:175-179.
31. Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet 2001;69:341-350.
32. Wiklund F, Jonsson BA, Goransson I, Bergh A, Grönberg H. Linkage analysis of prostate cancer susceptibility: Confirmation of linkage at 8p22-23. Hum Genet 2003;112:414-418.
33. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000;67:82-91.
34. Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, Goddard KA, Witte JS, Elston RC, Catalona WJ. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 2000;66:933-944.
35. Gibbs M, Stanford JL, Mclndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999;64:776-787.
36. Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL, Catalona WJ. Genome-wide scan for prostate cancer-aggressiveness loci. Am J Hum Genet 2000;67:92-99.
37. Neville PJ, Conti DV, Krumroy LM, Catalona WJ, Suarez BK, Witte JS, Casey G. Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer 2003;36: 332-339.
38. Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S, French AJ, Thibodeau SN. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet 2003;72:759-762.
39. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-325.
40. McPeek MS, Sun L. Statistical tests for detection of misspecified relationships by use of genome-screen data. Am J Hum Genet 2000;66:1076-1094.
41. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: A unified multipoint approach. Am J Hum Genet 1996;58:1347-1363.
42. Easton DF, Bishop DT, Ford D, Crockford GP, Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer - Results from 214 families. Am J Hum Genet 1993;52:678-701.
43. Smith CAB. Homogeneity test for linkage data. Proc. Sec. Int. Congr. Hum Genet 1961;1:212-213.
44. Lien S, Szyda J, Schechinger B, Rappold G, Arnheim N. Evidence for heterogeneity in recombination in the human pseudoautosomal region: High resolution analysis by sperm typing and radiation-hybrid mapping. Am J Hum Genet 2000;66:557-566.
45. Lander ES, Shork N. Genetic dissection of complex traits. Science 1994;265:2037-2048.
46. Sawcer S, Jones HB, Judge D, Visser F, Compston A, Goodfellow PN, Clayton D. Empirical genomewide significance levels established by whole genome simulations. Genet Epidemiol 1997;14:223-229.
47. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316.
48. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-3665.
49. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare MD, Ponder BAJ, Gayther SA, The Cancer Research UK/British Prostate Group UK Familial Prostate Cancer Study Collaborators, British Association of Urological Surgeons Section of Oncology, Easton DF, Eeles RA. Two percent of men with early onset prostate cancer harbor germline mutations in BRCA2. Am J Hum Genet 2003;72:1-12.